Celcuity Inc. (CELC) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Minneapolis, MN, 미국. 현재 CEO는 Brian F. Sullivan.
CELC 을(를) 보유 IPO 날짜 2017-09-20, 87 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $5.84B.
Celcuity Inc. is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, focused on developing molecularly targeted cancer therapies for patients in the United States. The company's proprietary CELsignia diagnostic platform analyzes living tumor cells to identify the specific cellular abnormalities driving a patient's cancer and determines the most appropriate targeted treatment approach. Its lead drug candidate, Gedatolisib, selectively targets PI3K and mTOR pathways and is being evaluated for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer under a license agreement with Pfizer. Celcuity is also advancing the CELsignia MP test, a laboratory-developed diagnostic that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor samples to guide therapeutic selection.
